Shortcomings in pharmacy benefit forecasting--interferon beta products.
Rich
Sheldon J
SJ
Meyer
Christina
C
D000276:Adjuvants, Immunologic / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000191:economics / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a